Development of Human Laboratory Study Model of Cocaine Relapse Prevention. - 1

This study is ongoing, but not recruiting participants.

First Received: June 18, 2002 Last Updated: October 23, 2007 History of Changes

Sponsored by:	National Institute on Drug Abuse (NIDA)
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00040066

Purpose

The purpose of this study is to assess the development of human laboratory study model of cocaine relapse prevention.

Condition	Intervention	Phase
Cocaine-Related Disorders	Procedure: Cocaine (IV)	Phase I

Drug Information available for: Cocaine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Double-Blind, Placebo Control, Parallel Assignment
Official Title:	Development of Human Laboratory Study Model of Cocaine Relapse Prevention

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Cocaine craving
Cocaine related high

Estimated Enrollment:	32
Study Start Date:	May 2002
Estimated Study Completion Date:	August 2003

Detailed Description:

The primary objective of this study will be to develop experimental procedures and parameters demonstrating arousal and craving responses to cocaine-related environmental cues as a model for future testing of the relapse prevention medication treatment of cocaine addiction.

Eligibility

Ages Eligible for Study:	18 Years to 55 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Cocaine dependent, non treatment seeking individuals

Exclusion Criteria:

Please contact site directly for details.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00040066

Locations

United States, California
UCLA Integrated Substance Abuse Program
Los Angeles, California, United States, 90024
United States, Texas
University of Texas Health Science Center
San Antonio, Texas, United States, 78284

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Investigators

Principal Investigator:

John Roache, Ph.D.

National Institute on Drug Abuse (NIDA)

More Information

No publications provided

Study ID Numbers:	NIDA-CTO-0013-1
Study First Received:	June 18, 2002
Last Updated:	October 23, 2007
ClinicalTrials.gov Identifier:	NCT00040066 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Cocaine-Related Disorders
Dopamine Uptake Inhibitors
Neurotransmitter Agents
Central Nervous System Depressants
Disorders of Environmental Origin
Anesthetics
Cardiovascular Agents
Anesthetics, Local

Dopamine
Mental Disorders
Substance-Related Disorders
Vasoconstrictor Agents
Dopamine Agents
Peripheral Nervous System Agents
Cocaine

Additional relevant MeSH terms:

Cocaine-Related Disorders
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Central Nervous System Depressants
Anesthetics
Disorders of Environmental Origin
Cardiovascular Agents
Anesthetics, Local

Pharmacologic Actions
Sensory System Agents
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Vasoconstrictor Agents
Dopamine Agents
Peripheral Nervous System Agents
Cocaine
Central Nervous System Agents

ClinicalTrials.gov processed this record on May 07, 2009